KURA Stock Rises More Than 15% This Past Week: Here's Why

Kura Oncology (KURA) shares rose 15.5% this past week after the FDA accepted its NDA with priority review for ziftomenib, a menin inhibitor, to treat relapsed or refractory acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation; a decision is expected by November 30, 2025. The NDA was based on positive phase II data, and the submission triggered a $45 million milestone payment from Kyowa Kirin, with whom Kura has a development and commercialization agreement.

Analysis

Kura Oncology's (KURA) shares surged 15.5% in the past week, significantly outperforming the industry's 0.1% decline, following the U.S. Food and Drug Administration's (FDA) acceptance of its New Drug Application (NDA) for ziftomenib. This NDA, granted priority review with a PDUFA target action date of November 30, 2025, seeks approval for ziftomenib to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation. A potential approval would establish ziftomenib as the first menin inhibitor for this AML subtype, reflecting the strongly positive sentiment (0.8 score) associated with this development. The NDA submission in the second quarter of 2025, based on the phase II KOMET-001 study which met its primary endpoint with statistically significant remission rates and a tolerable safety profile, also triggered a $45 million milestone payment to Kura from its development and commercialization partner, Kyowa Kirin, under an agreement from November 2024. Ziftomenib has previously received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA for this indication. Kura Oncology is also developing ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors and is progressing its pipeline with KO-2806, a next-generation farnesyl transferase inhibitor (FTI) for solid tumors, and tipifarnib, another FTI, for head and neck squamous cell carcinoma, with data from these programs anticipated later in 2025. These catalysts, particularly the ziftomenib NDA review, are expected to maintain Kura's momentum in 2025.

Key Decisions for Investors

• Investors should closely track the regulatory progress of ziftomenib towards its November 30, 2025 PDUFA date, as FDA approval would be a significant de-risking event and could unlock substantial market opportunity given its first-in-class potential.
• Upcoming clinical data readouts for other pipeline assets, KO-2806 and tipifarnib, expected later in 2025, should be monitored as they could provide further value drivers and demonstrate pipeline depth beyond ziftomenib.
• While the ziftomenib NDA acceptance and associated milestone payment are positive, the stock's current Zacks Rank #3 (Hold) warrants a balanced view, considering the inherent binary risks of FDA decisions and future clinical trial outcomes for a development-stage biotech company.